Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
Gihan Hamdy ElsisiMohamed M IbrahimKhaldoon Al-HumoodAnas Al-YousefPublished in: Journal of medical economics (2024)
The evidence generated by our model recommends the inclusion of SZC as a treatment option to correct HK and maintain normal serum K + level for CKD/HF patients within the Kuwaiti healthcare system. The costs saved from reducing frequent HK episodes, RAASis discontinuation/down titration, major cardiovascular events, and hospitalization offset the drug acquisition cost of SZC.
Keyphrases
- cardiovascular events
- heart failure
- end stage renal disease
- chronic kidney disease
- coronary artery disease
- newly diagnosed
- ejection fraction
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- acute heart failure
- left ventricular
- emergency department
- patient reported outcomes
- atrial fibrillation
- combination therapy
- endothelial cells
- adverse drug
- replacement therapy